INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 47 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $6,000 | +20.0% | 7,000 | 0.0% | 0.00% | – |
Q4 2020 | $5,000 | 0.0% | 7,000 | +16.7% | 0.00% | – |
Q3 2020 | $5,000 | 0.0% | 6,000 | 0.0% | 0.00% | – |
Q2 2020 | $5,000 | -99.8% | 6,000 | -99.7% | 0.00% | -100.0% |
Q4 2018 | $2,044,000 | -66.1% | 2,218,000 | -62.8% | 0.00% | -50.0% |
Q3 2018 | $6,031,000 | -13.5% | 5,968,000 | -25.1% | 0.00% | -33.3% |
Q2 2018 | $6,976,000 | +20.4% | 7,968,000 | +10.2% | 0.00% | 0.0% |
Q1 2018 | $5,792,000 | +219.5% | 7,229,000 | +217.1% | 0.00% | +200.0% |
Q4 2017 | $1,813,000 | +70.1% | 2,280,000 | +65.2% | 0.00% | – |
Q3 2017 | $1,066,000 | -78.3% | 1,380,000 | -72.7% | 0.00% | -100.0% |
Q2 2017 | $4,909,000 | -34.6% | 5,048,000 | -37.3% | 0.00% | -25.0% |
Q1 2017 | $7,502,000 | -43.0% | 8,050,000 | -45.5% | 0.00% | -42.9% |
Q4 2016 | $13,153,000 | +37.5% | 14,758,000 | +72.4% | 0.01% | +16.7% |
Q3 2016 | $9,569,000 | – | 8,558,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Silver Point Capital L.P. | 57,420,000 | $44,527,000 | 5.17% |
Birch Grove Capital LP | 10,003,000 | $7,934,000 | 4.14% |
PenderFund Capital Management Ltd. | 9,605,000 | $9,491,000 | 2.41% |
Context Capital Management, LLC | 9,887,000 | $7,671,000 | 1.05% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 57,791,000 | $45,738,000 | 0.90% |
DeepCurrents Investment Group LLC | 35,892,000 | $27,953,000 | 0.74% |
HIGHBRIDGE CAPITAL MANAGEMENT LLC | 22,977,000 | $18,267,000 | 0.70% |
WHITEBOX ADVISORS LLC | 23,150,000 | $17,847,000 | 0.56% |
ADVENT CAPITAL MANAGEMENT /DE/ | 27,397,000 | $21,720,000 | 0.46% |
OAKTREE CAPITAL MANAGEMENT LP | 19,435,000 | $15,079,000 | 0.26% |